Payment overview · 2025
General Payments
$447.54
24 reported records · 9 companies
Healthcare provider profile · identity verified
Ryan A Sullivan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MANISTEE, MI · NPI 1174605653
Verified facts
What the public records show
CMS Open Payments records show Ryan A Sullivan, MD received $447.54 in general payments during 2025 across 24 reported records.
ABBVIE INC. accounted for 39.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Skyclarys, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SKYCLARYS as an associated drug or biological on 3512 records involving 2165 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Skyclarys by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 300 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $174.78 | 39.0% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $65.49 | 14.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.43 | 9.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $41.48 | 9.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.79 | 8.9% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $24.05 | 5.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $21.13 | 4.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.99 | 4.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.40 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $447.54 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $145.33 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $42.43 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $41.48 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.79 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.63 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.89 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.45 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $27.36 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 300 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SKYCLARYS skyclarys |
2025 | Skyclarys | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 123 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | SKYCLARYS open payments reported associated product |
CMS Open Payments — General Payments 3512 supporting records · 2165 recipient NPIs · example record 1208299709 |
Skyclarys · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
123 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
300 | 49 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 863 | 218 |
| Levothyroxine Sodium | Levothyroxine Sodium | 642 | 146 |
| Lisinopril | Lisinopril | 574 | 165 |
| Omeprazole | Omeprazole | 510 | 138 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 435 | 66 |
| Gabapentin | Gabapentin | 427 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 406 | 99 |
| Losartan Potassium | Losartan Potassium | 388 | 108 |
| Tamsulosin Hcl | Tamsulosin Hcl | 376 | 100 |
| Metformin Hcl | Metformin Hcl | 347 | 92 |
| Hydrochlorothiazide | Hydrochlorothiazide | 329 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 306 | 82 |
| Simvastatin | Simvastatin | 303 | 76 |
| Eliquis | Apixaban | 300 | 49 |
| Furosemide | Furosemide | 291 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 280 | 78 |
| Alprazolam | Alprazolam | 203 | 32 |
| Allopurinol | Allopurinol | 200 | 45 |
| Montelukast Sodium | Montelukast Sodium | 183 | 45 |
| Potassium Chloride | Potassium Chloride | 170 | 43 |
| Atenolol | Atenolol | 165 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 164 | 61 |
| Carvedilol | Carvedilol | 160 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 159 | 49 |
| Tramadol Hcl | Tramadol Hcl | 156 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 150 | 39 |
| Meloxicam | Meloxicam | 141 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 124 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 123 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 30 |
| Sertraline Hcl | Sertraline Hcl | 106 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 100 | 32 |
| Famotidine | Famotidine | 94 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 24 |
| Glipizide | Glipizide | 92 | 17 |
| Prednisone | Prednisone | 92 | 48 |
| Januvia | Sitagliptin Phosphate | 91 | 17 |
| Celecoxib | Celecoxib | 87 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 15 |
| Donepezil Hcl | Donepezil Hcl | 81 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 24 |
| Xarelto | Rivaroxaban | 80 | 20 |
| Bupropion Xl | Bupropion Hcl | 76 | 19 |
| Lorazepam | Lorazepam | 75 | 19 |
| Warfarin Sodium | Warfarin Sodium | 74 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 25 |
| Memantine Hcl | Memantine Hcl | 69 | 11 |
| Trulicity | Dulaglutide | 69 | 11 |
| Spironolactone | Spironolactone | 68 | 21 |
| Invokana | Canagliflozin | 62 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | suppressed |
| Ezetimibe | Ezetimibe | 61 | 16 |
| Trazodone Hcl | Trazodone Hcl | 61 | 22 |
| Morphine Sulfate Er | Morphine Sulfate | 60 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 14 |
| Jardiance | Empagliflozin | 59 | 12 |
| Clotrimazole | Clotrimazole | 57 | 26 |
| Finasteride | Finasteride | 57 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 14 |
| Ibuprofen | Ibuprofen | 56 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 27 |
| Metformin Hcl Er | Metformin Hcl | 50 | 18 |
| Bumetanide | Bumetanide | 49 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | suppressed |
| Pregabalin | Pregabalin | 44 | suppressed |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 12 |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 38 | suppressed |
| Baclofen | Baclofen | 36 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | 11 |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Risperidone | Risperidone | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | 12 |
| Fentanyl | Fentanyl | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Azithromycin | Azithromycin | 29 | 26 |
| Glimepiride | Glimepiride | 29 | suppressed |
| Novolog Flexpen | Insulin Aspart | 29 | 11 |
| Ozempic | Semaglutide | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 17 |
| Ondansetron Odt | Ondansetron | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 20 |
| Methadone Hcl | Methadone Hcl | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 20 |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Calcitriol | Calcitriol | 24 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Jantoven | Warfarin Sodium | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Junel Fe | Norethindrone-E.Estradiol-Iron | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Paliperidone Er | Paliperidone | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Skyclarys | Omaveloxolone | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $447.54 · 24 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, ELIQUIS, FARXIGA, GARDASIL 9, NURTEC ODT, QULIPTA, SKYCLARYS, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VAXNEUVANCE, VRAYLAR, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error